The Orphan Drug Designation (ODD) is a status assigned by EMA to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.
We have summarized the work process for you to have always at hand.
Have a look at the complete process:
For further information, queries or assistance, contact us at: [email protected]
Search News & Events
Share
The EU pharmaceutical legislation is undergoing its most significant reform in more than two decades, reshaping the regulatory framework for medicines across Europe. This webinar
The objective of this project was to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for the different stages of osteoarthritis in order to get to develop an efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
